Refanezumab
- CAS No.
- 1233953-61-1
- Chemical Name:
- Refanezumab
- Synonyms
- Refanezumab;Refanezumab (anti-MAG);Research Grade Refanezumab;Research Grade Refanezumab(DHD43401)
- CBNumber:
- CB58080968
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | 3ZZ278643V |
Refanezumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0624069 | Refanezumab 99.9% | 1233953-61-1 | 1mg | $520 | 2026-06-04 | Buy |
| ChemScene | CS-0624069 | Refanezumab 99.9% | 1233953-61-1 | 5mg | $1625 | 2026-06-04 | Buy |
| ChemScene | CS-0624069 | Refanezumab 99.9% | 1233953-61-1 | 10mg | $2600 | 2026-06-04 | Buy |
| aablocks | AA02EO85 | Refanezumab ≥95%(SDS-PAGE&SEC-HPLC) | 1233953-61-1 | 1mg | $664 | 2026-06-03 | Buy |
| aablocks | AA02EO85 | Refanezumab ≥95%(SDS-PAGE&SEC-HPLC) | 1233953-61-1 | 5mg | $1660 | 2026-06-03 | Buy |
Refanezumab Chemical Properties,Uses,Production
Uses
Refanezumab (GSK249320) is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab can cross the blood-brain barrier (BBB) in animal stroke models. Refanezumab has the potential for the enhancement of recovery of function poststroke[1][2].
in vivo
Refanezumab (GSK249320; 10 mg/kg; IV; starting 24 hours post-stroke and continuing weekly for 6 more doses) shows larger increases in neuroscore and staircase test. Refanezumab by intravenous penetrates the lesion site and is associated with a small effect on functional outcomes when initiated 24 hours post-stroke[1].
| Animal Model: | Male Sprague Dawley rats (weight 361g)[1] |
| Dosage: | 10 mg/kg |
| Administration: | IV; starting 24 hours post-stroke and continuing weekly for 6 more doses; starting seven days post-stroke and continuing weekly for 5 more doses |
| Result: | Animals treated 24 hours post-stroke showed larger increases in neuroscore and staircase test as compared to controls, but animals treated 7 days post-stroke showed no significant behavioral benefit. |
References
[1] Diana Cash, et al. GSK249320, A Monoclonal Antibody Against the Axon Outgrowth Inhibition Molecule Myelin-Associated Glycoprotein, Improves Outcome of Rodents with Experimental Stroke. J Neurol Exp Neurosci. 2016;2(2):28-33. Epub 2016 Nov 21. PMID:28018988
[2] B Abila, et al. First-time-in-human study with GSK249320, a myelin-associated glycoprotein inhibitor, in healthy volunteers. Clin Pharmacol Ther. 2013 Feb;93(2):163-9. DOI:10.1038/clpt.2012.227
Refanezumab Preparation Products And Raw materials
Raw materials
Preparation Products
Refanezumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| Wuhan Acumen Bio-Technology Co.,ltd | 027-027-16602739303 16602739303 | 673003916@qq.com | China | 4593 | 58 |
| Shanghai Aladdin Biochemical Technology Co.,Ltd. | 6206333 13167063860 | anhua.mao@aladdin-e.com | China | 43379 | 58 |
